{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:13:10Z","timestamp":1792728790767,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40121-021-00456-0","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T11:02:47Z","timestamp":1624014167000},"page":"1531-1547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comparative Efficacy and Safety of Vancomycin, Linezolid, Tedizolid, and Daptomycin in Treating Patients with Suspected or Proven Complicated Skin and Soft Tissue Infections: An Updated Network Meta-Analysis"],"prefix":"10.1007","volume":"10","author":[{"given":"Jingjuan","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeli","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8828-5594","authenticated-orcid":false,"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"456_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1185\/03007990903454912","volume":"26","author":"M Bounthavong","year":"2010","unstructured":"Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr Med Res Opin. 2010;26:407\u201321.","journal-title":"Curr Med Res Opin"},{"key":"456_CR2","doi-asserted-by":"crossref","unstructured":"National Nosocomial Infections Surveillance (NNIS) Report, data summary from October 1986\u2013April 1996, issued May 1996: a report from the National Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1996;24:380\u20138.","DOI":"10.1016\/S0196-6553(96)90026-7"},{"key":"456_CR3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3201\/eid0702.010204","volume":"7","author":"HF Chambers","year":"2001","unstructured":"Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2001;7:178\u201382.","journal-title":"Emerg Infect Dis"},{"key":"456_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1056\/NEJMcp070747","volume":"357","author":"RS Daum","year":"2007","unstructured":"Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med. 2007;357:380\u201390.","journal-title":"N Engl J Med"},{"key":"456_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.amjmed.2006.01.004","volume":"119","author":"NF Crum","year":"2006","unstructured":"Crum NF, Lee RU, Thornton SA, et al. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med. 2006;119:943\u201351.","journal-title":"Am J Med"},{"key":"456_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2165\/00019053-200725090-00004","volume":"25","author":"AF Shorr","year":"2007","unstructured":"Shorr AF. Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics. 2007;25:751\u201368.","journal-title":"Pharmacoeconomics"},{"key":"456_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0149-2918(07)80085-3","volume":"29","author":"M McCollum","year":"2007","unstructured":"McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous\/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin Ther. 2007;29:469\u201377.","journal-title":"Clin Ther"},{"key":"456_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2015.03.011","volume":"46","author":"C Tsoulas","year":"2015","unstructured":"Tsoulas C, Nathwani D. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: are we any clearer? Int J Antimicrob Agents. 2015;46:1\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"456_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1086\/422458","volume":"39","author":"SE Cosgrove","year":"2004","unstructured":"Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis. 2004;39:539\u201345.","journal-title":"Clin Infect Dis"},{"key":"456_CR10","first-page":"A9","volume":"14","author":"M Basseti","year":"2013","unstructured":"Basseti M, Patel D, Chuang L, et al. An indirect comparison of clinical success of antimicrobial agents for confirmed methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infections (CSSTI). Surg Infect. 2013;14:A9.","journal-title":"Surg Infect"},{"key":"456_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/jac\/dkv411","volume":"71","author":"J Kingsley","year":"2016","unstructured":"Kingsley J, Mehra P, Lawrence LE, et al. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016;71:821\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"456_CR12","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jemermed.2015.07.026","volume":"49","author":"GJ Shaw","year":"2015","unstructured":"Shaw GJ, Meunier JM, Korfhagen J, et al. Randomized controlled noninferiority trial comparing daptomycin to vancomycin for the treatment of complicated skin and skin structure infections in an observation unit. J Emerg Med. 2015;49:928\u201336.","journal-title":"J Emerg Med"},{"key":"456_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jama.2013.241","volume":"309","author":"P Prokocimer","year":"2013","unstructured":"Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309:559\u201369.","journal-title":"JAMA"},{"key":"456_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ijantimicag.2012.08.004","volume":"40","author":"M Bally","year":"2012","unstructured":"Bally M, Dendukuri N, Sinclair A, Ahern SP, Poisson M, Brophy J. A network meta-analysis of antibiotics for treatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection. Int J Antimicrob Agents. 2012;40:479\u201395.","journal-title":"Int J Antimicrob Agents"},{"key":"456_CR15","first-page":"8","volume":"2019","author":"SH Lan","year":"2019","unstructured":"Lan SH, Lin WT, Chang SP, et al. Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis. Antibiotics (Basel). 2019;2019:8.","journal-title":"Antibiotics (Basel)."},{"key":"456_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13756-019-0518-2","volume":"8","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Wang Y, Van Driel ML, et al. Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia. Antimicrob Resist Infect Control. 2019;8:72.","journal-title":"Antimicrob Resist Infect Control"},{"key":"456_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3:80\u201397.","journal-title":"Res Synth Methods."},{"key":"456_CR18","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.handbookcochraneorg. 2011."},{"key":"456_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"456_CR20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"456_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JPT, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Internal Med. 2013;159:130\u20137.","journal-title":"Ann Internal Med."},{"key":"456_CR22","doi-asserted-by":"publisher","first-page":"e019703","DOI":"10.1136\/bmjopen-2017-019703","volume":"8","author":"MJ Page","year":"2018","unstructured":"Page MJ, McKenzie JE, Higgins JPT. Tools for assessing risk of reporting biases in studies and syntheses of studies: a systematic review. BMJ Open. 2018;8:e019703.","journal-title":"BMJ Open"},{"key":"456_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10156-012-0501-9","volume":"19","author":"N Aikawa","year":"2013","unstructured":"Aikawa N, Kusachi S, Mikamo H, et al. Efficacy and safety of intravenous daptomycin in Japanese patients with skin and soft tissue infections. J Infect Chemother. 2013;19:447\u201355.","journal-title":"J Infect Chemother"},{"key":"456_CR24","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12879-015-1261-9","volume":"15","author":"TL Kauf","year":"2015","unstructured":"Kauf TL, McKinnon P, Corey GR, et al. An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. BMC Infect Dis. 2015;15:503.","journal-title":"BMC Infect Dis"},{"key":"456_CR25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1742-1241.2008.01988.x","volume":"63","author":"PE Pertel","year":"2009","unstructured":"Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract. 2009;63:368\u201375.","journal-title":"Int J Clin Pract"},{"key":"456_CR26","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/j.1742-1241.2008.01854.x","volume":"62","author":"DE Katz","year":"2008","unstructured":"Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008;62:1455\u201364.","journal-title":"Int J Clin Pract"},{"key":"456_CR27","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.amjsurg.2009.08.045","volume":"199","author":"KMF Itani","year":"2010","unstructured":"Itani KMF, Dryden MS, Bhattacharyya H, Kunkel MJ, Baruch AM, Weigelt JA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010;199:804\u201316.","journal-title":"Am J Surg"},{"key":"456_CR28","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/jac\/dkm369","volume":"60","author":"S Kohno","year":"2007","unstructured":"Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother. 2007;60:1361\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"456_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ijantimicag.2008.04.004","volume":"32","author":"DF Lin","year":"2008","unstructured":"Lin DF, Zhang YY, Wu JF, et al. Linezolid for the treatment of infections caused by gram-positive pathogens in China. Int J Antimicrob Agents. 2008;32:241\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"456_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.amjsurg.2005.01.011","volume":"189","author":"JN Sharpe","year":"2005","unstructured":"Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005;189:425\u20138.","journal-title":"Am J Surg"},{"key":"456_CR31","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/340353","volume":"34","author":"DL Stevens","year":"2002","unstructured":"Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002;34:1481\u201390.","journal-title":"Clin Infect Dis"},{"key":"456_CR32","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","volume":"49","author":"J Weigelt","year":"2005","unstructured":"Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"456_CR33","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1086\/500139","volume":"42","author":"B Jaksic","year":"2006","unstructured":"Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42:597\u2013607.","journal-title":"Clin Infect Dis"},{"key":"456_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1086\/318486","volume":"32","author":"E Rubinstein","year":"2001","unstructured":"Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402\u201312.","journal-title":"Clin Infect Dis"},{"key":"456_CR35","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/S0149-2918(03)80118-2","volume":"25","author":"RG Wunderink","year":"2003","unstructured":"Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25:980\u201392.","journal-title":"Clin Ther"},{"key":"456_CR36","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1378\/chest.08-0011","volume":"134","author":"RG Wunderink","year":"2008","unstructured":"Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest. 2008;134:1200\u20137.","journal-title":"Chest"},{"key":"456_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/cid\/cir895","volume":"54","author":"RG Wunderink","year":"2012","unstructured":"Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54:621\u20139.","journal-title":"Clin Infect Dis"},{"key":"456_CR38","first-page":"63","volume":"2019","author":"X Lv","year":"2019","unstructured":"Lv X, Alder J, Li L, et al. Efficacy and safety of tedizolid phosphate versus linezolid in a randomized phase 3 trial in patients with acute bacterial skin and skin structure infection. Antimicrob Agents Chemother. 2019;2019:63.","journal-title":"Antimicrob Agents Chemother"},{"key":"456_CR39","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","volume":"14","author":"GJ Moran","year":"2014","unstructured":"Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14:696\u2013705.","journal-title":"Lancet Infect Dis"},{"key":"456_CR40","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2147\/TCRM.S115175","volume":"12","author":"C Liu","year":"2016","unstructured":"Liu C, Mao Z, Yang M, et al. Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis. Ther Clin Risk Manag. 2016;12:1455\u201366.","journal-title":"Ther Clin Risk Manag"},{"key":"456_CR41","first-page":"38","volume":"2018","author":"Y Li","year":"2018","unstructured":"Li Y, Xu W. Efficacy and safety of linezolid compared with other treatments for skin and soft tissue infections: a meta-analysis. Biosci Rep. 2018;2018:38.","journal-title":"Biosci Rep"},{"key":"456_CR42","doi-asserted-by":"publisher","first-page":"S172","DOI":"10.1097\/01.inf.0000088671.35064.7c","volume":"22","author":"R Yogev","year":"2003","unstructured":"Yogev R, Patterson LE, Kaplan SL, et al. Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J. 2003;22:S172\u20137.","journal-title":"Pediatr Infect Dis J"},{"key":"456_CR43","first-page":"3725","volume":"4","author":"R Evers","year":"2013","unstructured":"Evers R, Antony NL, Ogechika Alozie MD, Suresh Antony MD. Pilot study comparing daptomycin and telavancin in the treatment of skin and soft tissue infections. Internet J Infect Dis. 2013;4:3725\u20137.","journal-title":"Internet J Infect Dis."},{"key":"456_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijantimicag.2011.08.007","volume":"39","author":"SR Quist","year":"2012","unstructured":"Quist SR, Fierlbeck G, Seaton RA, Loeffler J, Chaves RL. Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections. Int J Antimicrob Agents. 2012;39:90\u20131.","journal-title":"Int J Antimicrob Agents"},{"key":"456_CR45","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673\u201381.","journal-title":"Clin Infect Dis"},{"key":"456_CR46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jiac.2018.01.010","volume":"24","author":"H Mikamo","year":"2018","unstructured":"Mikamo H, Takesue Y, Iwamoto Y, et al. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan\u2014results of a randomised, multicentre phase 3 study. J Infect Chemother. 2018;24:434\u201342.","journal-title":"J Infect Chemother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00456-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-021-00456-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00456-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T10:47:22Z","timestamp":1627555642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-021-00456-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["456"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00456-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]},"assertion":[{"value":"16 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}